1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 18th September 2023 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

.Norway study of Rituximab

Discussion in 'Drug and supplement treatments' started by Sue Klaus, Nov 11, 2017.

Tags:
  1. Sue Klaus

    Sue Klaus Established Member

    Messages:
    19
    Location:
    Markham, Illinois
    1. What blood test can be given to determine whether an MECFS patient has the proliferative B cells in their bloodstream, that rituximab and other drugs would eliminate from the bloodstream?
    2. Would it be helpful at all after receiving this kind of treatment to also have one or two sessions of dialysis, to clear out the detritus from the bloodstream that is left behind after the rituximab treatment?
    3. Is one of the reasons that this is possibly going to be helpful that clearing these proliferative b-cells would allow more space in the bloodstream for more red blood cells to be circulating, thus providing more oxygen to cells?
     
    Sue Klaus, Nov 11, 2017
    #1
    Awol, Inara and ivorin like this.
  2. Trish

    Trish Moderator Staff Member

    Messages:
    48,689
    Location:
    UK
    I'm hoping we'll get the answers to a lot of our questions when the Phase 3 trial results are published next year.

    I'm not an expert on any of this, but here's my take on a couple of your questions:

    2. Dialysis is used when the kidneys aren't functioning properly. I don't think there's any evidence that this is the case in ME.

    3. I doubt there's a problem with space in the bloodstream for other kinds of cells. I think it's more about getting rid of B cells that are doing the wrong thing in immunological terms - maybe producing autoimmune antibodies which hopefully the new generation B cells will not do.
     
    Trish, Nov 11, 2017
    #2
    Woolie and Andy like this.
  3. Rain

    Rain Senior Member (Voting Rights)

    Messages:
    180
    I do actually think they tried out dialysis in a few patients during the early stages of Rituximab trials. Seems like they quickly stepped away from it as it’s years ago and it has not been mentioned since.
     
    Rain, Nov 11, 2017
    #3
    Trish likes this.
  4. Adrian

    Adrian Administrator Staff Member

    Messages:
    6,326
    Location:
    UK
    I think there was a German team looking at antibodies who were doing a trial with some sort of blood filtering to try to remove anti-bodies. It should work more quickly than Rituximab but for a much shorter time. I think there was talk about doing that along with Rituximab so that any antibodies are cleared out by the filtering and then Rituximab kills of the b-cells stopping more anti-bodies being created.



    The theories are around getting rid of antibodies that are causing some harm - probably through some sort of signalling rather than just reducing b-cells. B-cells cause/control the production of antibodies. The delay in the action of Rituximab seems to support this theory.
     
    Adrian, Nov 11, 2017
    #4
    Inara, Woolie, Trish and 4 others like this.
  5. Gingergrrl

    Gingergrrl Senior Member (Voting Rights)

    Messages:
    637
    @Sue Klaus

    1) My understanding (which could be totally wrong!) is that it is not proliferative B cells, or an abnormal number of B cells, vs. B cells creating pathogenic auto-antibodies and Ritux stops the auto-abs at production level.

    2) I don't think dialysis would be diagnostically helpful vs. something like plasmapheresis or immunoadsorption might. In my case, having high dose IVIG first was diagnostically helpful.

    3) No idea re: the oxygen question!
     
    Gingergrrl, Nov 11, 2017
    #5
    Inara likes this.

Share This Page